NEW YORK (GenomeWeb) – Molecular diagnostics firm Atlas Genetics today announced the completion of a Series C financing round that raised $20 million. 

Atlas will use the proceeds to accelerate the launch of its MDx system called io in Europe for the ultra-rapid diagnosis of infectious diseases, initiate clinical trials in the US, and expand its test menu for sexually transmitted diseases and hospital-acquired infections. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.